我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

基于复杂网络的中医方剂治疗肺癌核心药物及其干预靶点分析*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2019年01期
页码:
77-82
栏目:
方药研究
出版日期:
2019-10-29

文章信息/Info

Title:
A Preliminary Study on the Core Drugs and Intervention Targets of Traditional Chinese Medicine Prescription for Lung Cancer Based on Complex Network
文章编号:
1000-2723(2019)01-0077-06
作者:
乔阳1刘震1郭利平1△李博1任明2
(1. 天津中医药大学,天津 300193;2. 天津中医药大学附属保康医院,天津 300193)
Author(s):
QIAO Yang1 LIU Zhen1 GUO Liping1 LI Bo1 REN Ming2
(1. Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China;2. Baokang Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China)
关键词:
肺癌 复杂网络 黄芪 磷脂酶D1(PLD1)
Keywords:
lung cancer complex network Astragalus membranaeus PLD1 gene target
分类号:
R273;R734.2
DOI:
10.19288/j.cnki.issn.1000-2723.2019.01.017
文献标识码:
A
摘要:
目的探讨中药方剂治疗肺癌的核心药物以及对其作用机制和效应靶点预测。方法通过复杂网络的方法基于近20年文献首先筛选中药方剂中治疗肺癌的主药,再通过中药网络药理学数据库以及TCGA肿瘤全基因组数据库,通过数据挖掘方法探讨预测主药治疗肺癌的机制及关键靶点,并通过大数据高通量全基因组信息观察调节关键靶点对肺癌患者生存期的影响。结果黄芪是肺癌治疗中医方药中的核心主药,不仅使用率最高并且与其他药物的配伍最多,能有效干预磷脂酶D1(phospholipaseD1,PLD1)基因靶点,而PLD1作为特异性基因在肺癌尤其是小细胞肺癌中呈现高表达,调节PLD1的表达可有效提高小细胞肺癌患者的生存率。结论黄芪是肺癌治疗方药中的核心主药,其机制可能是干预PLD1起作用。
Abstract:
Objective To explore the core herbs of traditional Chinese medicine prescriptions in the treatment of lung cancer and to predict their action mechanism and effect targets. Methods Based on the literature of the past twenty years, we first screened the main drugs for lung cancer in Chinese herbal prescriptions, and then explored the mechanism and key targets of the main drugs for lung cancer treatment by data mining through Chinese herbal network pharmacology database and TCGA tumor genome database, and then observed and adjusted the key points by large data and high throughput genome-wide information. Results Astragalus membranaceus is the core of Chinese medicine in the treatment of lung cancer, not only with the highest utilization rate but also with the most compatibility with other drugs, it can effectively interfere with PLD1 gene target, and PLD1 as a specific gene in lung cancer, especially in small cell lung cancer shows high expression, regulating PLD1. Conclusion Astragalus membranaceus is the core drug in the treatment of lung cancer, and its effective mechanism may be through the intervention of PLD1.

参考文献/References

[1] SIEGEL R L,MILLER K D,JEMAL A. Cancer statistics,2018 [J]. CA Cancer J Clin,2018,68(1):7-30.
[2] CHEN S,FLOWER A,RITCHIE A,et al. Oral Chinese herbal medicine(CHM)as an adjuvant treatment during chemotherapy for non-small cell lung cancer:A systematic review[J] . Lung Cancer,2009,68(2):137-145.
[3] GAO J,MORGAN W A,ALBERTO S M,et al. The ethanol extract of Scutellaria baicalensis and the active compounds induce cell cycle arrest and apoptosis including upregulation of p53 and Bax in human lung cancer cells[J]. Toxicol Appl Pharmacol,2011,254(3):221-228.
[4] KAO S J,SU J L,CHEN C K,et al. Osthole inhibits the invasive ability of human lung adenocarcinoma cells via suppression of NF-κB-mediated matrix metalloproteinase-9 expression[J]. Toxicol Appl Pharmacol,2012,261(1):105-115.
[5] 刘丽荣,徐凯. 中医药治疗晚期非小细胞肺癌研究现状[J]. 中国中医药信息杂志,2006,13(6):98-100.
[6] 国家药典委员会. 中华人民共和国药典:一部[M]. 北京:中国医药科技出版社,2010:6-13.
[7] 李澄,谢雁鸣,张寅,等. 基于关联规则Apriori算法的真实世界复方苦参注射液治疗乳腺恶性肿瘤西药联合应用特征研究[J]. 中南药学,2017,15(11):1513-1519.
[8] LIU Z Y,GUO F,WANG Y,et al. BATMAN-TCM:a bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine[J]. Sci Rep,2016(6):21146.
[9] Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. [J]. Nature,2011,474:609-615.
[10] 邓晓霞,李清宋,陈中,等. 黄芪抗肿瘤作用机制的研究进展[J]. 中药新药与临床药理,2016,27(2):307-312.
[11] 李杨,杨玲玲,白彦丽,等. 黄芪多糖对气阴两虚Lewis肺癌荷瘤小鼠肿瘤生长、转移及细胞周期的影响[J]. 肿瘤防治研究,2018,45(3):131-137.
[12] 王美阁. 黄芪多糖对非小细胞肺癌患者免疫功能的影响[J]. 光明中医,2017,32(3):335-337.
[13] 杨晶源,王立宏,王利. 黄芪甲苷抗人肺癌SPC-A-1细胞增殖作用及其机制[J]. 中成药,2016,38(8):1818-1820.
[14] 戴彭辰,刘一诚,何成诗,等. 黄芪口服液辅助化疗治疗老年肺癌的临床疗效及对免疫功能的影响[J]. 转化医学电子杂志,2016,3(5):1-3.
[15] 刘德志,蓝朝廷. 黄芪注射液在老年肺癌患者辅助化疗中的作用[J]. 中国初级卫生保健,2017,31(7):76-77.
[16] 桂雪梅,黄成亮,范贤明,等. 黄芪生脉饮用于非小细胞型肺癌辅助治疗的临床研究[J]. 中药药理与临床,2018,34(2):100-104.
[17] 熊绍权,罗秋月,李亚玲,等. 大黄芪汤联合化疗抑制晚期非小细胞肺癌新增转移的回顾性临床研究[J]. 成都中医药大学学报,2018,41(1):46-49.
[18] 高雅,曹函溦,胡天惠. 磷脂酶D在肿瘤发生中的作用机制研究进展[J]. 肿瘤防治研究,2013,40(9):899-902.
[19] 洪星辉,黄金玲. Wnt/β连环素和NF-κB信号通路对磷脂酶D的调控作用及其与肿瘤关系的研究进展[J]. 中国药理学与毒理学杂志,2014,28(5):779-783.
[20] 高敏娜,李昱. Wnt/β-catenin和NF-κB信号通路对肿瘤血管生成中VEGFs/VEGFRs的调控作用[J]. 生理科学进展,2013,44(1):72-74.
[21] ZHANG J W,BIAN Z H,ZHOU J L,et al. MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma[J]. Protein Cell,2015,6(9):680-688.
[22] XIAO J J,SUN Q,BEI Y H,et al. Therapeutic inhibition of phospholipase D1 suppresses hepatocellular carcinoma[J]. Clin Sci,2016,130(13):1125-1136.
[23] 李丽华,史健. 肿瘤微环境与肺癌相关性研究进展[J]. 中国肿瘤,2015,24(6):501-504.

备注/Memo

备注/Memo:
收稿日期: 2019 - 01- 16
* 基金项目: 国家中医药管理局行业专项(201107006);天津市滨海新区卫计委重点项目(2016BWKZ001);天津市教委科 研计划项目(2017KJ152);天津市科技计划项目(15ZXLCSY00020)
第一作者简介: 乔阳(1989-),女,在读博士研究生,主要从事中医老年病的研究。
△通信作者: 郭利平,Email:lpgtjn@163.com.cn
更新日期/Last Update: 2019-10-22